In addition to the drugs discussed in this section, numerous other Nrf2 inducers acting as electrophilic Keap1 modifiers have been or are currently being tested in clinical trials for the treatment of diseases/conditions such as kidney disease, diabetes, liver diseases (non-alcoholic fatty liver disease, and liver fibrosis and cirrhosis), and cancer. This evidence concerns the gene KEAP1 and cancer.